ERBB2 and neoplasm: A proportion of their cohort also had sequencing data on baseline tumour tissue available, and the authors reported an example where plasma taken at the time of cisplatin resistance showed persistence of ERBB2 and TP53 mutations identified in baseline tumour tissue alongside a new NF1 aberration.